Worth reading
53Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
57.5
Year-on-year revenue growth (%)Wording
Conditional
How definitive the wording is.Results for this period
First quarter2024年1月1日〜2024年3月31日ConsolidatedJapanese GAAPNet Sales4,354¥ millionYear on year +57.5%Progress 25.6%
Operating profit1,053¥ millionYear on year +523.7%Progress 28.8%
Ordinary income1,132¥ millionYear on year +406.4%Progress 29.8%
Net income attributable to owners of the parent779¥ millionYear on year +848.2%Progress 29.4%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share41.62円
Operating Margin24.2%
Financial position at period-end
Total assets29,789¥ million
of which net assets 25,346 ¥ millionEquity ratio 85.1%vs. prior year-end -1.3pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueJapan ¥1,857 million (YoY +77.4%), Taiwan ¥795 million (YoY +29.3%), 香港（香港、珠海） ¥509 million (YoY +60.6%), China (Suzhou) ¥755 million (YoY +67.9%), Europe ¥259 million (YoY +32.6%), Thailand ¥176 million (YoY +26.0%)
Segment profitJapan ¥686 million, Taiwan ¥132 million (YoY +114.3%), 香港（香港、珠海） ¥109 million (YoY +346.6%), China (Suzhou) ¥153 million, Europe ¥9 million (YoY +2,040.4%), Thailand ¥27 million
Regional sales¥1,857 million (YoY +77.4%), ¥795 million (YoY +29.3%), ¥509 million (YoY +60.6%), ¥755 million (YoY +67.9%), ¥259 million (YoY +32.6%), ¥176 million (YoY +26.0%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥17,000 million (YoY +21.3%)
Operating profit¥3,650 million (YoY +46.4%)
Ordinary income¥3,800 million (YoY +41.6%)
Net income¥2,650 million (YoY +15.0%)
Revision to Earnings ForecastNet Sales Not disclosed → ¥17,000 million / Operating profit Not disclosed → ¥3,650 million / Ordinary income Not disclosed → ¥3,800 million / Net income Not disclosed → ¥2,650 million
Annual Dividend Forecast¥45 → ¥45（0.0%）
Factors Behind Changes in Business Performance
為替や一部顧客における需要の前倒し等により売上高が過去最高となった。薬品需要の回復に伴う出荷数量の増加と、グローバル生産戦略における生産効率改善が利益に貢献した。
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidation重要な子会社の異動なし。新規・除外の会社数および社名はNot applicable
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥1,342 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥5,997 thousand
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (for institutional investors and analysts)
Issued Shares at Period-End20,071,093
Treasury Shares at Period-End1,346,241
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2024年1月1日〜2024年3月31日 |
| Net Sales | ¥4,354 million (YoY +57.5%) |
| Operating profit | ¥1,053 million (YoY +523.7%) |
| Ordinary income | ¥1,132 million (YoY +406.4%) |
| Profit attributable to owners of the parent | ¥779 million (YoY +848.2%) |
| Net income per share | 41.62円 |
| Operating Margin | 24.2% |
| Equity ratio | End of the current fiscal period 85.1% / End of previous period 86.4% |
| Total assets | ¥29,789 million |
| Net assets | ¥25,346 million |
| Full-year earnings forecast | Net Sales ¥17,000 million (YoY +21.3%) / Operating profit ¥3,650 million (YoY +46.4%) / Ordinary income ¥3,800 million (YoY +41.6%) / Net income ¥2,650 million (YoY +15.0%) |
| Revision to Earnings Forecast | Net Sales Not disclosed → ¥17,000 million / Operating profit Not disclosed → ¥3,650 million / Ordinary income Not disclosed → ¥3,800 million / Net income Not disclosed → ¥2,650 million |
| Annual Dividend Forecast | ¥45 → ¥45（0.0%） |
| Segment revenue | Japan ¥1,857 million (YoY +77.4%), Taiwan ¥795 million (YoY +29.3%), 香港（香港、珠海） ¥509 million (YoY +60.6%), China (Suzhou) ¥755 million (YoY +67.9%), Europe ¥259 million (YoY +32.6%), Thailand ¥176 million (YoY +26.0%) |
| Segment profit | Japan ¥686 million, Taiwan ¥132 million (YoY +114.3%), 香港（香港、珠海） ¥109 million (YoY +346.6%), China (Suzhou) ¥153 million, Europe ¥9 million (YoY +2,040.4%), Thailand ¥27 million |
| Regional sales | ¥1,857 million (YoY +77.4%), ¥795 million (YoY +29.3%), ¥509 million (YoY +60.6%), ¥755 million (YoY +67.9%), ¥259 million (YoY +32.6%), ¥176 million (YoY +26.0%) |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥1,342 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥5,997 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | 重要な子会社の異動なし。新規・除外の会社数および社名はNot applicable |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 20,071,093 |
| Treasury Shares at Period-End | 1,346,241 |
| Factors Behind Changes in Business Performance | 為替や一部顧客における需要の前倒し等により売上高が過去最高となった。薬品需要の回復に伴う出荷数量の増加と、グローバル生産戦略における生産効率改善が利益に貢献した。 |
Items this document does not state (10)
Cash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodPayout ratioShareholder Return PolicyOrders received and order backlogDepreciation and amortizationImpairment lossMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.為替や一部顧客における需要の前倒し、薬品需要の回復に伴う出荷数量の増加、グローバル生産戦略における生産効率改善が挙げられている。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.